![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
March 21, 2025
An update on the NCTN Grant; upcoming Group Meeting highlights; a perspective on the mistrust of science
March 21, 2025
Summaries of recently published ECOG-ACRIN and PrECOG research results
March 21, 2025
Summaries and links to timely information about research results presented at medical meetings, recognition of research leaders, and more
February 19, 2025
The co-chairs highlight the immense value of Cooperative Group cancer research and the importance of its continued funding
February 19, 2025
Patient-reported outcomes research has led to many discoveries that have influenced current research priorities and the way the Group designs its trials
December 23, 2024
The co-chairs reflect on the past year in cancer research and make the case for embracing the inclusion of real-world data in ECOG-ACRIN
November 25, 2024
Fall Group Meeting highlights; impactful results in head and neck cancer; a ComboMATCH update
November 25, 2024
In an annual evaluation, 54 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
September 17, 2024
Fall Comis Symposium to focus on inflammation as a cause of cancer; ECOG-ACRIN readies for NCTN Grant resubmission
September 17, 2024
A conversation with study chair James M. Ford, MD
September 17, 2024
This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial
September 17, 2024
A recent amendment expands eligibility for this phase 2 trial evaluating the use of green tea catechin pills to help prevent progression